BiologicalDrug
Oregovomab clinical trials
Also written MAb-B43.13.
- studies test it
- 15
- open now
- 0
- in phase 3
- 2
- first study started
- 1998
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
15 studies that test it; most in 1998 (2)
| Year | Studies |
|---|---|
| 1998 | 2 |
| 2000 | 1 |
| 2002 | 2 |
| 2004 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2017 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 12
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 3
CanariaBio Inc. (5) · Unither Pharmaceuticals (4) · National Cancer Centre, Singapore (2) · AltaRex (2) · University of Nebraska (1) · Quest PharmaTech Inc. (1)
Often tested with
Tested in the same studies.
Nivolumab (2) · Bevacizumab (1) · Paclitaxel (1) · Carboplatin (1) · Niraparib (1) · Nelfinavir (1) · Poly ICLC (1) · Antineoplastic Agents (1)
Studies
Open first, then newest update. How each study uses oregovomab is read from its arms, and is right about nine times in ten.
Testing it · 15
- Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian CancerActive, not recruitingPhase 2CanariaBio Inc.NCT05605535Written as Oregovomab
- Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerActive, not recruitingPhase 1/2CanariaBio Inc.NCT04938583Written as Oregovomab
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.Active, not recruitingPhase 2CanariaBio Inc.NCT05335993Written as Oregovomab
- Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryActive, not recruitingPhase 3CanariaBio Inc.NCT04498117Written as Oregovomab
- Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic CancerCompletedPhase 2University of NebraskaNCT01959672Written as Oregovomab
- Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginTerminatedPhase 1/2National Cancer Centre, SingaporeNCT03100006Written as Oregovomab
- Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginStatus unknownPhase 1/2National Cancer Centre, SingaporeNCT04620954Written as Oregovomab
- The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian CancerTerminatedPhase 1CanariaBio Inc.NCT03162562Written as Oregovomab
- A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian CancerCompletedPhase 2Quest PharmaTech Inc.NCT01616303Written as oregovomab
- Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and ChemotherapyStatus unknownPhase 2AltaRexNCT00003634Written as oregovomab
- Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal CancerStatus unknownPhase 2AltaRexNCT00004064Written as oregovomab
- Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian CarcinomaTerminatedPhase 2Unither PharmaceuticalsNCT00034372Written as oregovomab
- A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial CarcinomaTerminatedPhase 1/2Unither PharmaceuticalsNCT00034138Written as oregovomab
- Clinical Trial for Ovarian Cancer (OvaRex®)TerminatedPhase 3Unither PharmaceuticalsNCT00050375Written as oregovomab
- Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer TreatmentTerminatedPhase 2Unither PharmaceuticalsNCT00086632Written as oregovomab
Given in every arm · 1 — oregovomab is usual care beside what is tested
Codes
What other systems call oregovomab · ClinicalTrials.gg INT004006
- MeSH (NLM) C107428oregovomabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) HX101E7L6SOREGOVOMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7101491OregovomabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1784OregovomabOne source FDA
- DrugBank DB04964One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C107428 | oregovomab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | HX101E7L6S | OREGOVOMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7101491 | Oregovomab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1784 | Oregovomab | One source FDA |
| DrugBank | DB04964 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.